IGC Pharma (IGC) Notes Payables (2011 - 2026)

IGC Pharma's (IGC) quarterly Notes Payables came in at $27000.0 in Q1 2026, up 800.0% quarter-over-quarter from $3000.0 in Q2 2022.

Analysis

IGC Pharma (IGC) Notes Payables (2011 - 2026) Analysis & Trends

IGC Pharma (IGC) has reported Notes Payables for 12 consecutive years, with $27000.0 the latest figure, recorded in Q1 2026.

On a quarterly basis, Notes Payables changed N/A year-over-year to $27000.0 in Q1 2026; TTM through Mar 2026 was $27000.0, a N/A change from a year earlier, with the FY2026 full-year figure at $27000.0, changed N/A from the prior year.
Notes Payables was $27000.0 for Q1 2026 at IGC Pharma, up from $3000.0 in the prior quarter.
Over five years, Notes Payables peaked at $27000.0 in Q1 2026 and troughed at $3000.0 in Q1 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn
10	IGC Pharma	27.77 Mn	27.51 Mn	-

Historic Data

Download Data